# Axel Hoos

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/axel-hoos/

## Facts

| Field | Value |
| --- | --- |
| Citations | 42,548 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 68 |
| i10-index | 134 |
| Last Known Institution | GlaxoSmithKline (United States) |
| OpenAlex ID | https://openalex.org/A5086481435 |
| ORCID iD | https://orcid.org/0000-0001-5269-9376 |
| Works | 318 |

## Researcher papers

- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [Defining the critical hurdles in cancer immunotherapy](https://scholariq.org/papers/defining-the-critical-hurdles-in-cancer-immunotherapy/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Researcher university

- [GlaxoSmithKline (United States)](https://scholariq.org/institutions/glaxosmithkline-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.